Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel

doi:10.3389/fphar.2020.601513

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24048

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24048

Title:	Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
Authors:	Chang, LW;Hung, SC;Li, JR;Chiu, KY;Yang, CK;Chen, CS;Lu, KV;Chen, CC;Wang, SC;Lin, CY;Cheng, CL;Ou, YC;Yang, SF;Hsu, CY;Ho, SH;Wang, SS
Keywords:	geriatric nutritional risk index;metastasis castration resistant prostate cancer;chemotherapy;DOCETAXEL;survival
Date:	2021
Issue Date:	2022-08-05T09:46:59Z (UTC)
Publisher:	FRONTIERS MEDIA SA
ISSN:	1663-9812
Abstract:	Purpose: To investigate the prognostic efficacy of the Geriatric Nutritional Risk Index (GNRI) in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) receiving docetaxel as the first line of treatment. Methods: We retrospectively reviewed patients with mCRPC and receiving first line docetaxel in Taichung Veterans General Hospital from 2006 to 2012. The GNRI was calculated using serum albumin and body mass index, with a poor nutritional status defined as GNRI Results: One-hundred seventy patients with mCRPC were included. One-hundred twenty-five patients were of normal nutritional status (GNRI >= 92) and 45 patients were of poor nutritional status (GNRI <92). The cumulative docetaxel dosage was 600 (360-1,185) mg in the normal nutritional status group and 360 (127.5-660) mg in the poor nutritional status group (p < 0.001). The median overall survival from mCRPC was 30.39 months in the good nutritional status group and 11.07 months in the poor nutritional status group (p of log rank <0.001). In a multivariate model, poor nutritional status was an independent risk factor in overall survival (Hazard Ratio [HR] = 5.37, 95% Confidence Interval [CI] 3.27-8.83), together with a high metastatic volume (HR = 4.03, 95% CI 2.16-7.53) and docetaxel cumulative dosage (HR = 0.999, 95% CI 0.999-0.9998). Conclusion: Poor nutritional status with a GNRI <92 is associated with shorter progression free survival and overall survival in mCRPC patients treated with docetaxel. Metastatic volume and cumulative docetaxel dosage are also independent prognostic factors in overall survival.
URI:	http://dx.doi.org/10.3389/fphar.2020.601513 https://www.webofscience.com/wos/woscc/full-record/WOS:000615720300001 https://ir.csmu.edu.tw:8080/handle/310902500/24048
Relation:	FRONTIERS IN PHARMACOLOGY ,2021,v11
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	170	View/Open

Loading...